Close
Nordic 9Nordic 9

TCGX (investor - Venture Capital)

United States tcgcrossover.com
See something wrong or missing? Let us know
Offices:San Francisco

TCG Crossover is an American science-driven investment firm dedicated to advancing disruptive medicines

Average round investment:131.25M USD
Average number per year:4.0
Distribution: 2024 (4)
Portfolio companies: Denmark AdcendoUnited Kingdom VicebioUnited Kingdom Beacon Therapeutics See the entire list
Mostly invests in: United Kingdom United Kingdom (3) Health services (4)
See the entire list

Showing 3 of 4 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to TCGX

Name Criteria
United States KKR
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Denmark
  • Average number of deals per year: 3.6
  • Active last 12 months: Yes
France Korelya Capital
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.3
  • Active last 12 months: Yes
Sweden Nordic Capital
83%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Denmark
  • Average number of deals per year: 2.9
  • Active last 12 months: Yes
United States Logos Capital
82%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Denmark
  • Average number of deals per year: 2.0
  • Active last 12 months: Yes
United Kingdom Intermediate Capital Group
82%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.8
  • Active last 12 months: Yes
United States General Atlantic
82%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Denmark
  • Average number of deals per year: 4.2
  • Active last 12 months: Yes
United States Patient Square Capital
82%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.3
  • Active last 12 months: Yes
United States Fidelity Investments
82%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 3.4
  • Active last 12 months: Yes
United States Avego Bioscience Capital
81%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 1.0
  • Active last 12 months: Yes
Canada Omers Ventures
81%
  • Range for average deal size: 100M+ USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: United Kingdom
  • Average number of deals per year: 5.0
  • Active last 12 months: Yes
Top